Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Portage Biotech Inc ( (PRTG) ) has provided an announcement.
On July 31, 2025, AlphaTON Capital Corp entered into an At-The-Market Offering Agreement with Chardan Capital Markets, LLC, allowing the company to sell ordinary shares worth up to $2,841,450. This agreement, facilitated through a shelf registration statement, enables the company to raise capital by offering shares in various transactions, including block and private sales, enhancing its financial flexibility and market presence.
Spark’s Take on PRTG Stock
According to Spark, TipRanks’ AI Analyst, PRTG is a Neutral.
Portage Biotech Inc. exhibits significant financial weaknesses, such as no revenue and persistent losses, which heavily weigh down the overall score. Despite strong technical indicators suggesting bullish momentum, the poor valuation metrics and financial performance hinder the stock’s attractiveness. The absence of earnings call data or notable corporate events leaves these factors out of consideration.
To see Spark’s full report on PRTG stock, click here.
More about Portage Biotech Inc
AlphaTON Capital Corp, formerly known as Portage Biotech Inc, is a company organized under the laws of the British Virgin Islands. The company operates in the financial sector and is involved in the issuance and sale of ordinary shares, focusing on leveraging capital markets to raise funds.
Average Trading Volume: 105,338
Technical Sentiment Signal: Sell
Current Market Cap: $15.86M
Find detailed analytics on PRTG stock on TipRanks’ Stock Analysis page.